Compare IRIX & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRIX | CELU |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 17.3M |
| IPO Year | 1996 | N/A |
| Metric | IRIX | CELU |
|---|---|---|
| Price | $1.12 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 39.0K | ★ 168.4K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,593,000.00 | N/A |
| Revenue This Year | $3.07 | N/A |
| Revenue Next Year | $6.66 | $76.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $0.56 |
| 52 Week High | $1.65 | $4.35 |
| Indicator | IRIX | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 47.55 |
| Support Level | $1.01 | $0.69 |
| Resistance Level | $1.18 | $0.96 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 53.22 |
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.